SEOM Clinical Guidelines for Localized Rectal Cancer
Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated December 1, 2025
The SEOM (Spanish Society of Medical Oncology) Clinical Guidelines for localized rectal cancer emphasize a comprehensive, multidisciplinary approach to ensure optimal treatment outcomes. Below is a detailed overview based on the context provided:
1. Accurate Staging Is Critical
- Pelvic MRI is the gold standard for staging localized rectal cancer. It provides detailed information on tumor depth, nodal involvement, circumferential resection margin (CRM) status, mesorectal fascia involvement, and extramural venous invasion (EMVI).
- Accurate staging is essential for determining prognosis and guiding treatment strategies.
2. Multidisciplinary Management
- All cases of rectal cancer should be discussed in a multidisciplinary tumor board. This ensures coordinated input from oncologists, radiologists, surgeons, and pathologists, leading to individualized treatment plans and improved outcomes.
3. Universal MMR/MSI Testing
- Mismatch repair (MMR) or microsatellite instability (MSI) testing is mandatory for all newly diagnosed rectal cancer patients. Results are critical for assessing prognosis and determining eligibility for immunotherapy, especially in cases of deficient mismatch repair (dMMR).
4. Tumor Location and Classification
- Rectal cancers are classified based on their distance from the anal verge into low, middle, or high rectal tumors.
- Tumor location impacts surgical options (e.g., sphincter preservation) and the feasibility of organ-preserving strategies.
5. Early-Stage Disease Management
- For early-stage disease (e.g., pT1 tumors with favorable histology), local excision or endoscopic approaches may be considered. However, a meticulous histopathologic risk assessment is required to ensure safe management.
6. Standard Surgical Approach: Total Mesorectal Excision (TME)
- Total Mesorectal Excision (TME) is the standard curative surgical technique for localized rectal cancer. When performed with high technical quality, TME minimizes local recurrence and optimizes oncologic outcomes.
7. Neoadjuvant Therapy Options
- Total Neoadjuvant Therapy (TNT) is increasingly used for locally advanced rectal cancer. It combines chemotherapy and radiation before surgery to:
- Improve tumor response.
- Reduce distant recurrence risk.
- Enable organ preservation strategies in cases of complete clinical response.
8. Organ Preservation and Watch-and-Wait Strategies
- TNT can lead to complete clinical response, making nonoperative management a viable option for selected patients. This avoids surgery and preserves rectal function.
- The Watch-and-Wait approach is considered safe for patients with documented complete response, with outcomes comparable to immediate surgery. Intensive surveillance protocols are required to monitor for regrowth.
9. Radiotherapy Personalization
- Radiotherapy options include short-course or long-course regimens, tailored to tumor risk and location. Care must be taken to avoid overtreatment in low-risk cases.
10. Chemotherapy Sequencing
- Consolidation chemotherapy after chemoradiation increases complete response rates and enhances the feasibility of organ preservation.
11. High-Risk Disease Management
- Patients with high-risk features (e.g., threatened margins, EMVI, or nodal involvement) benefit most from TNT. Risk-adapted treatment intensification improves disease control and reduces recurrence.
12. Limited Role of Adjuvant Chemotherapy
- After modern neoadjuvant therapy approaches, adjuvant chemotherapy offers modest benefits. Its use should be individualized based on patient risk factors and response to prior treatment.
13. Immunotherapy for dMMR Rectal Cancer
- Checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) demonstrate dramatic responses in patients with dMMR rectal cancer. In selected cases, immunotherapy may replace chemoradiation.
14. Elderly and Frail Patients
- Treatment decisions for older or frail individuals should prioritize quality of life. A comprehensive geriatric assessment is recommended to tailor therapies to the patient's overall health and functional status.
15. Local Excision Post-Neoadjuvant Therapy
- For small residual tumors after neoadjuvant therapy, local excision may reduce morbidity compared to radical surgery. This approach is reserved for carefully selected patients.
16. Long-Term Survivorship Care
- Survivorship care should address:
- Recurrence surveillance.
- Management of functional outcomes and quality of life.
- Lifestyle counseling and symptom management.
Key Takeaways
- Personalized treatment based on tumor staging, location, and risk factors is essential.
- TNT and organ preservation strategies are revolutionizing rectal cancer management.
- Multidisciplinary care and intensive surveillance protocols are critical for optimizing outcomes.
- Emerging therapies like immunotherapy are transforming care for dMMR rectal cancer.
The SEOM guidelines align with international standards, emphasizing evidence-based, patient-centered approaches to ensure the best oncologic and functional outcomes for localized rectal cancer patients.
